Depletion of adipocyte sphingosine kinase 1 leads to cell hypertrophy, impaired lipolysis, and nonalcoholic fatty liver disease

Sphingolipids have become established participants in the pathogenesis of obesity and its associated maladies. Sphingosine kinase 1 (SPHK1), which generates S1P, has been shown to increase in liver and adipose of obese humans and mice and to regulate inflammation in hepatocytes and adipose tissue, i...

Full description

Bibliographic Details
Main Authors: Andrea K. Anderson, Johana M. Lambert, David J. Montefusco, Bao Ngan Tran, Patrick Roddy, William L. Holland, L. Ashley Cowart
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:Journal of Lipid Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520437009
id doaj-cbb13923fd534ddfa828e7356b19f332
record_format Article
spelling doaj-cbb13923fd534ddfa828e7356b19f3322021-04-29T04:39:17ZengElsevierJournal of Lipid Research0022-22752020-10-01611013281340Depletion of adipocyte sphingosine kinase 1 leads to cell hypertrophy, impaired lipolysis, and nonalcoholic fatty liver diseaseAndrea K. Anderson0Johana M. Lambert1David J. Montefusco2Bao Ngan Tran3Patrick Roddy4William L. Holland5L. Ashley Cowart6Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA; Departments of Biochemistry and Molecular Biology Medical University of South Carolina, Charleston, SC, USADepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA; Departments of Biochemistry and Molecular Biology Medical University of South Carolina, Charleston, SC, USADepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USADepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USADepartment of Regenerative Medicine, Medical University of South Carolina, Charleston, SC, USADepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, UT, USADepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA; Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, VA, USA; For correspondence: L. Ashley Cowart; For correspondence: L. Ashley CowartSphingolipids have become established participants in the pathogenesis of obesity and its associated maladies. Sphingosine kinase 1 (SPHK1), which generates S1P, has been shown to increase in liver and adipose of obese humans and mice and to regulate inflammation in hepatocytes and adipose tissue, insulin resistance, and systemic inflammation in mouse models of obesity. Previous studies by us and others have demonstrated that global sphingosine kinase 1 KO mice are protected from diet-induced obesity, insulin resistance, systemic inflammation, and NAFLD, suggesting that SPHK1 may mediate pathological outcomes of obesity. As adipose tissue dysfunction has gained recognition as a central instigator of obesity-induced metabolic disease, we hypothesized that SPHK1 intrinsic to adipocytes may contribute to HFD-induced metabolic pathology. To test this, we depleted Sphk1 from adipocytes in mice (SK1fatKO) and placed them on a HFD. In contrast to our initial hypothesis, SK1fatKO mice displayed greater weight gain on HFD and exacerbated impairment in glucose clearance. Pro-inflammatory cytokines and neutrophil content of adipose tissue were similar, as were levels of circulating leptin and adiponectin. However, SPHK1-null adipocytes were hypertrophied and had lower basal lipolytic activity. Interestingly, hepatocyte triacylglycerol accumulation and expression of pro-inflammatory cytokines and collagen 1a1 were exacerbated in SK1fatKO mice on a HFD, implicating a specific role for adipocyte SPHK1 in adipocyte function and inter-organ cross-talk that maintains overall metabolic homeostasis in obesity. Thus, SPHK1 serves a previously unidentified essential homeostatic role in adipocytes that protects from obesity-associated pathology. These findings may have implications for pharmacological targeting of the SPHK1/S1P signaling axis.http://www.sciencedirect.com/science/article/pii/S0022227520437009sphingosine-1-phosphatesphingolipidhigh-fat dietobesitymetabolic diseaseadipose
collection DOAJ
language English
format Article
sources DOAJ
author Andrea K. Anderson
Johana M. Lambert
David J. Montefusco
Bao Ngan Tran
Patrick Roddy
William L. Holland
L. Ashley Cowart
spellingShingle Andrea K. Anderson
Johana M. Lambert
David J. Montefusco
Bao Ngan Tran
Patrick Roddy
William L. Holland
L. Ashley Cowart
Depletion of adipocyte sphingosine kinase 1 leads to cell hypertrophy, impaired lipolysis, and nonalcoholic fatty liver disease
Journal of Lipid Research
sphingosine-1-phosphate
sphingolipid
high-fat diet
obesity
metabolic disease
adipose
author_facet Andrea K. Anderson
Johana M. Lambert
David J. Montefusco
Bao Ngan Tran
Patrick Roddy
William L. Holland
L. Ashley Cowart
author_sort Andrea K. Anderson
title Depletion of adipocyte sphingosine kinase 1 leads to cell hypertrophy, impaired lipolysis, and nonalcoholic fatty liver disease
title_short Depletion of adipocyte sphingosine kinase 1 leads to cell hypertrophy, impaired lipolysis, and nonalcoholic fatty liver disease
title_full Depletion of adipocyte sphingosine kinase 1 leads to cell hypertrophy, impaired lipolysis, and nonalcoholic fatty liver disease
title_fullStr Depletion of adipocyte sphingosine kinase 1 leads to cell hypertrophy, impaired lipolysis, and nonalcoholic fatty liver disease
title_full_unstemmed Depletion of adipocyte sphingosine kinase 1 leads to cell hypertrophy, impaired lipolysis, and nonalcoholic fatty liver disease
title_sort depletion of adipocyte sphingosine kinase 1 leads to cell hypertrophy, impaired lipolysis, and nonalcoholic fatty liver disease
publisher Elsevier
series Journal of Lipid Research
issn 0022-2275
publishDate 2020-10-01
description Sphingolipids have become established participants in the pathogenesis of obesity and its associated maladies. Sphingosine kinase 1 (SPHK1), which generates S1P, has been shown to increase in liver and adipose of obese humans and mice and to regulate inflammation in hepatocytes and adipose tissue, insulin resistance, and systemic inflammation in mouse models of obesity. Previous studies by us and others have demonstrated that global sphingosine kinase 1 KO mice are protected from diet-induced obesity, insulin resistance, systemic inflammation, and NAFLD, suggesting that SPHK1 may mediate pathological outcomes of obesity. As adipose tissue dysfunction has gained recognition as a central instigator of obesity-induced metabolic disease, we hypothesized that SPHK1 intrinsic to adipocytes may contribute to HFD-induced metabolic pathology. To test this, we depleted Sphk1 from adipocytes in mice (SK1fatKO) and placed them on a HFD. In contrast to our initial hypothesis, SK1fatKO mice displayed greater weight gain on HFD and exacerbated impairment in glucose clearance. Pro-inflammatory cytokines and neutrophil content of adipose tissue were similar, as were levels of circulating leptin and adiponectin. However, SPHK1-null adipocytes were hypertrophied and had lower basal lipolytic activity. Interestingly, hepatocyte triacylglycerol accumulation and expression of pro-inflammatory cytokines and collagen 1a1 were exacerbated in SK1fatKO mice on a HFD, implicating a specific role for adipocyte SPHK1 in adipocyte function and inter-organ cross-talk that maintains overall metabolic homeostasis in obesity. Thus, SPHK1 serves a previously unidentified essential homeostatic role in adipocytes that protects from obesity-associated pathology. These findings may have implications for pharmacological targeting of the SPHK1/S1P signaling axis.
topic sphingosine-1-phosphate
sphingolipid
high-fat diet
obesity
metabolic disease
adipose
url http://www.sciencedirect.com/science/article/pii/S0022227520437009
work_keys_str_mv AT andreakanderson depletionofadipocytesphingosinekinase1leadstocellhypertrophyimpairedlipolysisandnonalcoholicfattyliverdisease
AT johanamlambert depletionofadipocytesphingosinekinase1leadstocellhypertrophyimpairedlipolysisandnonalcoholicfattyliverdisease
AT davidjmontefusco depletionofadipocytesphingosinekinase1leadstocellhypertrophyimpairedlipolysisandnonalcoholicfattyliverdisease
AT baongantran depletionofadipocytesphingosinekinase1leadstocellhypertrophyimpairedlipolysisandnonalcoholicfattyliverdisease
AT patrickroddy depletionofadipocytesphingosinekinase1leadstocellhypertrophyimpairedlipolysisandnonalcoholicfattyliverdisease
AT williamlholland depletionofadipocytesphingosinekinase1leadstocellhypertrophyimpairedlipolysisandnonalcoholicfattyliverdisease
AT lashleycowart depletionofadipocytesphingosinekinase1leadstocellhypertrophyimpairedlipolysisandnonalcoholicfattyliverdisease
_version_ 1721502201610764288